Evidence map›Paper›PMID 31011343›Full record

ArticleIranian journal of pharmaceutical research : IJPR2018

Design, Synthesis, Molecular Modeling,

Zeynab Alimi Livani, Mahdieh Safakish, Zahra Hajimahdi, Sepehr Soleymani, Rezvan Zabihollahi, Mohammad Reza Aghasadeghi, Eskandanr Alipour, Afshin Zarghi

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zeynab Alimi LivaniDepartment of Organic Chemistry, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Mahdieh SafakishDepartment of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra HajimahdiDepartment of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sepehr SoleymaniHepatitis and AIDS department, Pasteur institute of Iran, Tehran, Iran.
Rezvan ZabihollahiHepatitis and AIDS department, Pasteur institute of Iran, Tehran, Iran.
Mohammad Reza AghasadeghiHepatitis and AIDS department, Pasteur institute of Iran, Tehran, Iran.
Eskandanr AlipourDepartment of Organic Chemistry, Tehran North Branch, Islamic Azad University, Tehran, Iran.
Afshin ZarghiDepartment of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some new diazo incorporated coumarin compounds were designed and synthesized to evaluate their anti-HIV activity. Overall, compounds were active against HIV at 100 μM. Additionally, no cytotoxic effect was observed at this concentration. The compound with 4-chlorobenzyl group indicated the best anti-HIV activity (52%). Docking studies using the later crystallographic data available for PFV integrase showed similar binding modes to HIV-1 integrase inhibitors. On the basis of these data, nitrogen atoms of 1,3,4-oxadiazole ring have been involved in the Mg

Indexed as

134-OxadiazoleADMEAnti-HIVDiazocoumarinDockingSynthesis

Identifiers

PMID31011343
PMCPMC6447871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.